title: Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
abstract: OBJECTIVE
  To compare the efficacy of low-fluence photodynamic therapy (PDT) and PDT with half-dose verteporfin in chronic central serous chorioretinopathy (CSC).
  
  
  METHODS
  The medical records of 64 eyes from 60 patients with chronic CSC were retrospectively reviewed; 36 eyes received low-fluence PDT (25 J/cm(2)) and 28 eyes received half-dose verteporfin PDT (3 mg/m(2)). The primary outcome measure was the proportion of eyes with complete resolution of subretinal fluid. Secondary outcome measures were the changes in best corrected visual acuity (BCVA) and central foveal thickness, and the proportion of eyes that showed an increase of ≥5 letters in BCVA at the last visit.
  
  
  RESULTS
  The mean follow-up period was 12.5±4.3 months and 13.1±4 months in the low-fluence group and half-dose group, respectively (P=0.568). Thirty-three eyes (91.6%) in the low-fluence group and 26 eyes (92.8%) in the half-dose verteporfin group showed complete resolution of subretinal fluid (P=0.703). BCVA increased by a mean of 7.4 letters and 4.8 letters in the low-fluence group and half-dose group, respectively (P=0.336). Seventeen eyes (52.8%) in the low-fluence group and 14 eyes (50%) in the half-dose group experienced a gain of ≥5 letters in BCVA (P=0.825). In the low-fluence and half-dose verteporfin group, the mean baseline central foveal thickness was 351±90 μm and 341±96 μm, and significantly decreased to 188±61 μm and 181±47 μm, respectively (P<0.01).
  
  
  CONCLUSIONS
  Both treatments resulted in complete subretinal fluid resolution in most of the eyes, with significantly better visual acuity outcomes compared to baseline at the last visit.
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Alkin
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Irfan
authors.initials: I
authors.lastname: Perente
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Ozkaya
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Dilek
authors.initials: D
authors.lastname: Alp
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Alper
authors.initials: A
authors.lastname: Agca
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Ebru Demet
authors.initials: ED
authors.lastname: Aygit
authors.affiliation: Hacettepe University Faculty of Science, Department of Statistics, Ankara, Turkey.
authors.forename: Selcuk
authors.initials: S
authors.lastname: Korkmaz
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Ahmet Taylan
authors.initials: AT
authors.lastname: Yazici
authors.affiliation: Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Demirok
keywords: central serous chorioretinopathy; half-dose verteporfin; low-fluence; photodynamic therapy
references.citation: Retina. 2006 Feb;26(2):239-42
references.pmid: 16467692
references.citation: Retina. 2003 Dec;23(6):752-63
references.pmid: 14707823
references.citation: J Ocul Pharmacol Ther. 2014 May;30(4):359-65
references.pmid: 24456481
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1315-23
references.pmid: 19421764
references.citation: Am J Ophthalmol. 2012 Mar;153(3):474-480.e1
references.pmid: 22019224
references.citation: Am J Ophthalmol. 2010 Feb;149(2):307-315.e2
references.pmid: 19896635
references.citation: Retina. 1994;14(3):231-42
references.pmid: 7973118
references.citation: Retina. 2008 Jan;28(1):85-93
references.pmid: 18185143
references.citation: Retina. 2002 Feb;22(1):19-24
references.pmid: 11884873
references.citation: Retina. 2011 Jan;31(1):119-26
references.pmid: 20890242
references.citation: Retina. 2013 Feb;33(2):309-15
references.pmid: 23095766
references.citation: Am J Ophthalmol. 2005 Jan;139(1):87-99
references.pmid: 15652832
references.citation: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4290-6
references.pmid: 18515567
references.citation: Retina. 2003 Jun;23(3):288-98
references.pmid: 12824827
references.citation: Br J Ophthalmol. 2006 Jul;90(7):869-74
references.pmid: 16597666
references.citation: Am J Ophthalmol. 1996 Jan;121(1):26-34
references.pmid: 8554078
references.citation: Am J Ophthalmol. 1982 Jul;94(1):91-6
references.pmid: 7091289
references.citation: Br J Ophthalmol. 2003 Dec;87(12):1453-8
references.pmid: 14660450